Effect of Iranian Borage on the management of Covid-19 symptoms

Evaluation of the effectiveness of Iranian Borage Aerial Part infusion on the management of Covid-19 mild to moderate symptoms: a clinical trial

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201016049048N1

Enrollment

Registered

2020-11-04

Start date

2020-11-07

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

corona virus (covid-19). COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Patients in the intervention group will receive Iranian Borage Aerial Part infusion (1 g/100 cc water) TID for 5 days in addition to the routine treatment. Interven

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with COVID-19 confirmed by RT-PCR and Ground glass view on CT scan Patients with COVID-19 symptoms (such as fever, muscle pain, chest discomfort, cough, reduced CBC and platelets, increased CRP and ESR) who have been exposed to suspected people in the last 14 days Having a conscious consent form signed to participate in the study Not participating in similar studies at the same time

Exclusion criteria

Exclusion criteria: People with a history of allergy to herbal medicines Having liver, kidney and cardiovascular diseases Permanent use of psychiatric drugs Pregnant and breastfeeding women People who can't swallow Having endocrine diseases like diabetes

Design outcomes

Primary

Measure	Time frame
Fever. Timepoint: At the beginning and end of the study. Method of measurement: Digital thermometer.;Respiratory status. Timepoint: At the beginning and end of the study. Method of measurement: Observation.;White blood cell count. Timepoint: At the beginning and end of the study. Method of measurement: Blood sample test.;Platelet blood count. Timepoint: At the beginning and end of the study. Method of measurement: Blood sample test.;Erythrocyte Sedimentation Rate. Timepoint: At the beginning and end of the study. Method of measurement: Blood sample test.;C-reactive protein. Timepoint: At the beginning and end of the study. Method of measurement: Blood sample test.;Vital capacity. Timepoint: At the beginning and end of the study. Method of measurement: Observation.	—

Measure

Time frame

Fever. Timepoint: At the beginning and end of the study. Method of measurement: Digital thermometer.;Respiratory status. Timepoint: At the beginning and end of the study. Method of measurement: Observation.;White blood cell count. Timepoint: At the beginning and end of the study. Method of measurement: Blood sample test.;Platelet blood count. Timepoint: At the beginning and end of the study. Method of measurement: Blood sample test.;Erythrocyte Sedimentation Rate. Timepoint: At the beginning and end of the study. Method of measurement: Blood sample test.;C-reactive protein. Timepoint: At the beginning and end of the study. Method of measurement: Blood sample test.;Vital capacity. Timepoint: At the beginning and end of the study. Method of measurement: Observation.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad mehdi Zarshenas

Shiraz University of Medical Sciences

zarm@sums.ac.ir+98 71 3242 4127

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026